RU2019108100A - Композиции никотинамид рибозида и птеростильбена и методы лечения нейродегенеративных заболеваний - Google Patents
Композиции никотинамид рибозида и птеростильбена и методы лечения нейродегенеративных заболеваний Download PDFInfo
- Publication number
- RU2019108100A RU2019108100A RU2019108100A RU2019108100A RU2019108100A RU 2019108100 A RU2019108100 A RU 2019108100A RU 2019108100 A RU2019108100 A RU 2019108100A RU 2019108100 A RU2019108100 A RU 2019108100A RU 2019108100 A RU2019108100 A RU 2019108100A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- composition
- pterostilbene
- neurodegenerative disease
- nicotinamide riboside
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 18
- 239000000203 mixture Substances 0.000 title claims 13
- 208000015122 neurodegenerative disease Diseases 0.000 title claims 10
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title claims 5
- 235000020956 nicotinamide riboside Nutrition 0.000 title claims 5
- 239000011618 nicotinamide riboside Substances 0.000 title claims 5
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 title claims 5
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 title claims 5
- 230000004770 neurodegeneration Effects 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010044565 Tremor Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 206010001540 Akathisia Diseases 0.000 claims 1
- 206010002653 Anosmia Diseases 0.000 claims 1
- 206010006100 Bradykinesia Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010013642 Drooling Diseases 0.000 claims 1
- 206010013887 Dysarthria Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000006083 Hypokinesia Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010031127 Orthostatic hypotension Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000001431 Psychomotor Agitation Diseases 0.000 claims 1
- 206010071390 Resting tremor Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000008630 Sialorrhea Diseases 0.000 claims 1
- 102000011990 Sirtuin Human genes 0.000 claims 1
- 108050002485 Sirtuin Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 231100000870 cognitive problem Toxicity 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 210000005064 dopaminergic neuron Anatomy 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000008921 facial expression Effects 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000005021 gait Effects 0.000 claims 1
- 208000018879 impaired coordination Diseases 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000001144 postural effect Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 claims 1
- 208000026473 slurred speech Diseases 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378053P | 2016-08-22 | 2016-08-22 | |
| US62/378,053 | 2016-08-22 | ||
| PCT/US2017/047979 WO2018039207A1 (en) | 2016-08-22 | 2017-08-22 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019108100A true RU2019108100A (ru) | 2020-09-22 |
| RU2019108100A3 RU2019108100A3 (https=) | 2020-11-27 |
Family
ID=61246253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019108100A RU2019108100A (ru) | 2016-08-22 | 2017-08-22 | Композиции никотинамид рибозида и птеростильбена и методы лечения нейродегенеративных заболеваний |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11260069B2 (https=) |
| EP (1) | EP3500267A4 (https=) |
| JP (1) | JP7132907B2 (https=) |
| KR (1) | KR20190046895A (https=) |
| CN (2) | CN115645432A (https=) |
| AU (1) | AU2017316614B2 (https=) |
| BR (1) | BR112019003579A2 (https=) |
| CA (1) | CA3034673A1 (https=) |
| MX (1) | MX2019002211A (https=) |
| RU (1) | RU2019108100A (https=) |
| WO (1) | WO2018039207A1 (https=) |
| ZA (1) | ZA201901536B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3500267A4 (en) | 2016-08-22 | 2020-03-18 | Elysium Health, Inc. | NICOTINAMIDRIBOSIDE AND PTEROSTILLE COMPOSITIONS AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES |
| WO2018213715A1 (en) * | 2017-05-18 | 2018-11-22 | Elysium Health, Inc. | Methods and compositions for improving sleep |
| SG11201912267SA (en) | 2017-06-19 | 2020-01-30 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| WO2019023471A1 (en) * | 2017-07-28 | 2019-01-31 | Centers For Age Control, Inc. | COMPOSITIONS AND METHODS FOR PREVENTING AND INVERTING THE ASPECTS OF AGING |
| US20220072019A1 (en) * | 2018-10-19 | 2022-03-10 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor |
| WO2020102326A1 (en) * | 2018-11-13 | 2020-05-22 | Elysium Health, Inc | Methods for determining and increasing nad levels |
| WO2020131578A2 (en) | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| WO2020176445A1 (en) * | 2019-02-26 | 2020-09-03 | Universitat De Valencia-Estudi General | Methods and compositions for treating motor neuron diseases |
| CN110812365A (zh) * | 2019-11-07 | 2020-02-21 | 明特奇点医疗科技（北京）有限公司 | 一种组合物及其制备方法与制剂 |
| CN111838669B (zh) * | 2020-08-07 | 2022-11-29 | 四川大学华西医院 | 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途 |
| EP4029496A1 (en) * | 2021-01-18 | 2022-07-20 | Universitat de València | Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases |
| EP4079311B1 (en) | 2021-04-20 | 2025-10-01 | Nuvamid SA | Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism |
| WO2022269064A1 (en) * | 2021-06-24 | 2022-12-29 | Vestlandets Innovasjonsselskap As (Vis) | Nad-augmentation therapy for parkinson's disease |
| EP4284387B1 (en) | 2021-06-24 | 2024-07-31 | Vestlandets Innovasjonsselskap As (Vis) | Nad-augmentation therapy for parkinson's disease |
| WO2023076804A1 (en) * | 2021-10-27 | 2023-05-04 | Elysium Health Inc. | Methods for treatment of menopausal syndromes |
| CN121793959A (zh) | 2023-06-14 | 2026-04-03 | 可劳迈戴斯有限公司 | 静脉内配制品中的烟酰胺核苷及其衍生物与使用方法 |
| CN116807985A (zh) * | 2023-06-20 | 2023-09-29 | 风火轮(上海)生物科技有限公司 | 一种烟酰胺核糖组合物及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008501343A (ja) * | 2004-06-04 | 2008-01-24 | ワシントン・ユニバーシティ | 神経障害を治療するための方法および組成物 |
| US20060229265A1 (en) | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20090069444A1 (en) | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
| US20090163580A1 (en) * | 2007-12-24 | 2009-06-25 | Natrol, Inc. | Anti-aging composition containing resveratrol and method of administration |
| WO2010095926A1 (en) | 2009-02-20 | 2010-08-26 | N.V. Nutricia | Use of reveratrol for preserving cognitive functioning |
| US9737495B2 (en) | 2009-06-22 | 2017-08-22 | Indus Biotech Private Limited | Process for obtaining purified pterostilbene and methods of use thereof |
| WO2011011721A2 (en) | 2009-07-24 | 2011-01-27 | Amazentis Sa | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| US9439875B2 (en) | 2011-05-11 | 2016-09-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Anxiolytic effect of pterostilbene |
| EP2574339A1 (de) * | 2011-09-27 | 2013-04-03 | Johannes Huber | Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen |
| US20130149277A1 (en) | 2011-12-13 | 2013-06-13 | Cliffstar Llc | Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders |
| US20130296440A1 (en) * | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
| KR20220098049A (ko) * | 2013-10-30 | 2022-07-08 | 크로마덱스 아이엔씨. | 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물 |
| JP2017518306A (ja) | 2014-06-02 | 2017-07-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用 |
| WO2016122832A1 (en) * | 2015-01-30 | 2016-08-04 | Natural Formulations | Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries |
| US20180071273A1 (en) * | 2015-03-17 | 2018-03-15 | Speccialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| EP3500267A4 (en) | 2016-08-22 | 2020-03-18 | Elysium Health, Inc. | NICOTINAMIDRIBOSIDE AND PTEROSTILLE COMPOSITIONS AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES |
-
2017
- 2017-08-22 EP EP17844270.3A patent/EP3500267A4/en not_active Withdrawn
- 2017-08-22 US US16/327,651 patent/US11260069B2/en active Active
- 2017-08-22 CA CA3034673A patent/CA3034673A1/en active Pending
- 2017-08-22 CN CN202211250881.3A patent/CN115645432A/zh active Pending
- 2017-08-22 CN CN201780064669.9A patent/CN109982706A/zh active Pending
- 2017-08-22 JP JP2019510843A patent/JP7132907B2/ja active Active
- 2017-08-22 WO PCT/US2017/047979 patent/WO2018039207A1/en not_active Ceased
- 2017-08-22 AU AU2017316614A patent/AU2017316614B2/en active Active
- 2017-08-22 RU RU2019108100A patent/RU2019108100A/ru not_active Application Discontinuation
- 2017-08-22 MX MX2019002211A patent/MX2019002211A/es unknown
- 2017-08-22 BR BR112019003579-6A patent/BR112019003579A2/pt not_active Application Discontinuation
- 2017-08-22 KR KR1020197008293A patent/KR20190046895A/ko not_active Ceased
-
2019
- 2019-03-12 ZA ZA2019/01536A patent/ZA201901536B/en unknown
-
2022
- 2022-01-21 US US17/580,999 patent/US11998561B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018039207A1 (en) | 2018-03-01 |
| CA3034673A1 (en) | 2018-03-01 |
| US20190201426A1 (en) | 2019-07-04 |
| AU2017316614B2 (en) | 2023-06-15 |
| EP3500267A4 (en) | 2020-03-18 |
| JP7132907B2 (ja) | 2022-09-07 |
| AU2017316614A1 (en) | 2019-03-21 |
| KR20190046895A (ko) | 2019-05-07 |
| US11260069B2 (en) | 2022-03-01 |
| US20220143055A1 (en) | 2022-05-12 |
| ZA201901536B (en) | 2024-06-26 |
| EP3500267A1 (en) | 2019-06-26 |
| BR112019003579A2 (pt) | 2019-05-21 |
| CN109982706A (zh) | 2019-07-05 |
| MX2019002211A (es) | 2019-10-30 |
| US11998561B2 (en) | 2024-06-04 |
| JP2019524856A (ja) | 2019-09-05 |
| CN115645432A (zh) | 2023-01-31 |
| RU2019108100A3 (https=) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019108100A (ru) | Композиции никотинамид рибозида и птеростильбена и методы лечения нейродегенеративных заболеваний | |
| JP2019524856A5 (https=) | ||
| DiMascio et al. | A controlled trial of amantadine in drug-induced extrapyramidal disorders | |
| CN115884761A (zh) | 大麻素的透皮药物制剂 | |
| RU2011134499A (ru) | Композиция 4-амино-2-(2,6-диоксопиперидин-3-ил)изоиндолин-1,3-диона | |
| RU2009148288A (ru) | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна | |
| JP2018533622A5 (https=) | ||
| KR20150002640A (ko) | 파킨슨병을 치료하기 위한 신규의 치료적 접근법 | |
| AU2002340971B2 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders | |
| US5837701A (en) | Composition and method for treating conditions associated with symptoms of unspecified retarded maturation | |
| Tsarkov et al. | Use of pramipexole in neuropsychiatry | |
| KR20070011276A (ko) | 쿠에티아핀 항정신병제를 사용한 정신병의 치료 | |
| JP2016528171A5 (https=) | ||
| WO2005105120A2 (en) | Pharmaceutical combination, active on central nervous system (cns) and set of pharmaceuticals; method of treatment of cns-disorders; means facilitating penetration of the hematoencephalic barrier; pharmaceutical means for endonasal administration | |
| JPWO2008099781A1 (ja) | アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 | |
| RU2469734C2 (ru) | Лечебное средство для лечения расстройств аккомодаций "stiak" | |
| Zier et al. | Procyclidine hydrochloride (Kemadrin) treatment of parkinsonism: Result in 108 patients | |
| CN118159267A (zh) | 用于治疗神经退行性眼病的普利多匹定及其类似物 | |
| Gupta et al. | Levosulpiride: A review | |
| Bhatt et al. | Parkinson's disease | |
| CN109640975B (zh) | 组胺-3受体反向激动剂与乙酰胆碱酯酶抑制剂的组合 | |
| CA3033050C (en) | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist | |
| WO2022129410A1 (en) | Masitinib for the treatment of alzheimer's disease | |
| CN1290166A (zh) | 运动障碍的治疗 | |
| JP3494651B2 (ja) | 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210331 |